(Company Registration No. 199206445M)

Metech International Limited

(Incorporated in the Republic of Singapore)

Condensed interim financial statements
For the three months and six months ended 30 June 2026

*Metech International Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to inform the shareholders of the Company that pursuant to Rules 705(2)(e) and 705(2C) of the Singapore Exchange Securities Trading Limited's (the "**Exchange**") Listing Manual Section B: Rules of Catalist (the "**Catalist Rules**"), the Company is required to announce its quarterly financial statements in view of the material uncertainty relating to going concern disclosed in the Company's financial statements for the financial year ended 31 December 2025.*

*This announcement has been reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.

METech

(Company Registration No. 199206445M)

Table of contents

M00ETech

(Company Registration No. 199206445M)

UNAUDITED FINANCIAL STATEMENTS FOR THE THREE MONTHS ("Q2FY") AND SIX MONTHS ("HY") ENDED 30 JUNE 2026

A. Condensed interim consolidated statement of profit or loss and other comprehensive income

		The Group			The Group		
		3-months period ended 30/06/2026 (Q2FY2026) Unaudited	3-months period ended 30/06/2025 (Q2FY2025) Unaudited	Inc/(Dec)	**6-months period ended 30/06/2026 (HY2026) Unaudited**	6-months period ended 30/06/2025 (HY2025) Unaudited	Inc/(Dec)
	Note	**S$'000**	**S$'000**	**%**	**S$'000**	**S$'000**	**%**
Revenue	4	**1,288**	1,521	(15.32)	**3,210**	3,061	4.87
Cost of sales		**(1,041)**	(1,275)	(18.35)	**(2,605)**	(2,723)	(4.33)
Gross profit		**247**	246	0.41	**605**	338	78.99
Gross profit margin		**19.18%**	16.17%		**18.85%**	11.04%	
Other income:							
Others	6	**209**	2	n.m.	**366**	6	n.m.
Interest income		*	-	n.m.	*	*	n.m.
Expenses:							
Administrative expenses		**(351)**	(355)	(1.13)	**(623)**	(711)	(12.38)
Finance costs		**-**	(2)	n.m.	**-**	(5)	n.m.
Profit/(Loss) before income tax	7	**105**	(109)		**348**	(372)	
Income tax expense	8	**-**	-	n.m.	**-**	-	n.m.
Profit/(Loss) after income tax		**105**	(109)		**348**	(372)	
Discontinued operations							
Loss from discontinued operations		**(*)**	(10)	n.m.	**(*)**	(27)	n.m.
Total profit/(loss)		**105**	(119)		**348**	(399)	
Other comprehensive income/(loss), net of income tax:							
Foreign currency translation difference		**2**	(3)	n.m.	**16**	(2)	n.m.
Total comprehensive income/(loss) for the financial period		**107**	(122)		**364**	(401)	
Profit/(Loss) attributable to:							
Equity holders of the Company		**105**	(117)	n.m.	**348**	(394)	n.m.
Non-controlling interests		**(*)**	(2)	n.m.	**(*)**	(5)	n.m.
		105	(119)		**348**	(399)	
Total profit/(loss) attributable to equity holders of the Company							
Profit/(Loss) from continuing operations		**105**	(109)	n.m.	**348**	(372)	n.m.
Loss from discontinued operations		**(*)**	(8)	n.m.	**(*)**	(22)	n.m.
		105	(117)		**348**	(394)	
Total comprehensive profit/(loss) for the period attributable to:							
Equity holders of the Company		**107**	(120)		**364**	(396)	
Non-controlling interests		**(*)**	(2)		**(*)**	(5)	
		107	(122)		**364**	(401)	

	Note	The Group			The Group		
		3-months period ended 30/06/2026 (Q2FY2026) Unaudited	3-months period ended 30/06/2025 (Q2FY2025) Unaudited	Inc/(Dec)	**6-months period ended 30/06/2026 (HY2026) Unaudited**	6-months period ended 30/06/2025 (HY2025) Unaudited	Inc/(Dec)
		S$'000	**S$'000**	**%**	**S$'000**	**S$'000**	**%**
Basic and diluted profit/(loss) per share (cents per share) attributable to the equity holders of the Company							
Continuing operations		**0.05**	(0.06)		**0.17**	(0.21)	
Discontinued operations		**(*)**	(*)		**(*)**	(0.01)	
Total		**0.05**	(0.06)		**0.17**	(0.22)	

Notes:
(1) * denotes amounts less than S$1,000 or amounts less than 0.01 cents per share (as applicable)
(2) n.m. means not meaningful

The calculation of basic and diluted loss per ordinary share was based on a weighted average of 203,874,833 shares from 1 January 2026 to 30 June 2026 (1 January 2025 to 30 June 2025: 178,505,931).

B. Condensed interim statements of financial position

		The Group		The Company	
		As at 30/06/2026 Unaudited	As at 31/12/2025 Audited	As at 30/06/2026 Unaudited	As at 31/12/2025 Audited
	Note	S$'000	S$'000	S$'000	S$'000
ASSETS					
Non-current Assets					
Property, plant and equipment	11	40	44	-	1
Investments in subsidiaries	12	-	-	-	-
Total Non-current Assets		40	44	-	1
Current Assets					
Inventories	13	-	-	-	-
Trade and other receivables	14	6,343	2,264	1,302	14
Cash and bank balances	15	11	198	4	3
Assets of disposal group classified as held for sale	16	8	8		-
Total Current Assets		6,362	**2,470**	1,306	**17**
Total Assets		**6,402**	**2,514**	**1,306**	**18**
EQUITY AND LIABILITIES					
Equity attributable to owners of the Company					
Share capital	17	192,010	190,510	192,010	190,510
Translation reserve	18	10	(6)		-
Other reserves	18	(319)	(319)	-	-
Accumulated losses		(190,251)	(190,599)	(192,141)	(191,965)
		1,450	(414)	(131)	(1,455)
Non-controlling interests	19	(983)	(983)	-	-
Total Equity		**467**	**(1,397)**	**(131)**	**(1,455)**
LIABILITIES					
Current Liabilities					
Trade and other payables	20	5,789	3,753	1,437	1,473
Liabilities directly associated with disposal group classified as held for sale	16	146	158	-	-
Total Current Liabilities		5,935	**3,911**	1,437	**1,473**
Total Liabilities		5,935	3,911	1,437	1,473
Total Equity and Liabilities		**6,402**	**2,514**	**1,306**	**18**

C. Condensed interim statements of changes in equity

	Share capital	Translation reserves	Other reserves	Accumulated losses	Total equity attributable to owners of the Company	Non-controlling interests	Total
	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000
The Group							
2026							
Balance at 1 January 2026	190,510	(6)	(319)	(190,599)	(414)	(983)	(1,397)
Profit for the financial period	-	-	-	348	348	*	348
Other comprehensive income -							
Foreign currency translation	-	16	-	-	16	-	16
Total comprehensive gain for the financial period	-	16	-	348	364	*	364
Issuance of ordinary shares (non-cash)	1,500	-	-	-	1,500	-	1,500
Balance at 30 June 2026	192,010	10	(319)	(190,251)	1,450	(983)	467
2025							
Balance at 1 January 2025	189,710	20	(319)	(190,095)	(684)	(997)	(1,681)
Loss for the financial period	-	-	-	(394)	(394)	(5)	(399)
Other comprehensive loss -							
Foreign currency translation	-	(2)	-	-	(2)	-	(2)
Total comprehensive loss for the financial period	-	(2)	-	(394)	(396)	(5)	(401)
Issuance of ordinary shares (non-cash)	504	-	-	-	504	-	504
Balance at 30 June 2025	190,214	18	(319)	(190,489)	(576)	(1,002)	(1,578)

The Company	Share capital S$'000	Accumulated losses S$'000	Total S$'000
2026			
Balance at 1 January 2026	190,510	(191,965)	(1,455)
Loss for the financial period	-	(176)	(176)
Total comprehensive loss for the financial period	-	(176)	(176)
Issuance of ordinary shares (non-cash)	1,500	-	1,500
Balance as at 30 June 2026	192,010	(192,141)	(131)
2025			
Balance at 1 January 2025	189,710	(191,110)	(1,400)
Loss for the financial period	-	(398)	(398)
Total comprehensive loss for the financial period	-	(398)	(398)
Issuance of ordinary shares (non-cash)	504	-	504
Balance as at 30 June 2025	190,214	(191,508)	(1,294)

D. Condensed interim consolidated statement of cash flows

		The Group		The Group	
		3-months period ended 30/06/2026 (Q2FY2026) Unaudited	3-months period ended 30/06/2025 (Q2FY2025) Unaudited	**6-months period ended 30/06/2026 (HY2026) Unaudited**	6-months period ended 30/06/2025 (HY2025) Unaudited
	Note	**S$'000**	**S$'000**	**S$'000**	**S$'000**
Cash flows from operating activities					
Profit/(Loss) before income tax, from continuing operation		105	(109)	348	(372)
Loss before income tax, from discontinuing operation		(*)	(10)	(*)	(27)
		105	(119)	348	(399)
Adjustments for:					
Depreciation of plant and equipment		2	31	4	62
Interest income		*	*	*	*
Interest expense		-	2	-	5
Operating profit/(loss) before working capital changes		107	(86)	352	(332)
Changes in working capital					
Trade and other receivables		(1,993)	(1,399)	(4,080)	(1,729)
Trade and other payables		1,119	793	2,543	(82)
Cash used in operating activities		(767)	(692)	(1,185)	(2,143)
Interest received		*	*	*	*
Net cash used in operating activities		**(767)**	**(692)**	**(1,185)**	**(2,143)**
Cash flows from investing activities					
Additions of plant and equipment		-	(4)	-	(4)
Proceeds from disposal of plant and equipment		-	-	-	119
Net cash (used in)/generated from investing activities		-	(4)	-	115

	Note	The Group		The Group	
		3-months period ended 30/06/2026 (Q2FY2026) Unaudited	3-months period ended 30/06/2025 (Q2FY2025) Unaudited	**6-months period ended 30/06/2026 (HY2026) Unaudited**	6-months period ended 30/06/2025 (HY2025) Unaudited
	Note	**S$'000**	**S$'000**	**S$'000**	**S$'000**
Cash flows from financing activities					
Proceeds from loan from an employee		768	931	982	931
Repayment of lease liabilities		-	(22)	-	(43)
Interest on lease liabilities		-	(2)	-	(5)
Net cash generated from financing activities		**768**	**907**	**982**	**883**
Net increase/(decrease) in cash and cash equivalents		1	211	(203)	(1,145)
Cash and cash equivalents at beginning of financial period		8	112	198	1,467
Effect of currency translation on cash and cash equivalents		2	(3)	16	(2)
Cash and cash equivalents at end of the financial period	15	11	320	11	320

Note:
* denotes values less than S$1,000

E. Notes to the condensed interim consolidated financial statements

1. Corporate information

Metech International Limited (the "**Company**") is incorporated and domiciled in Singapore and whose shares are listed and publicly traded on the Catalist Board of the Singapore Exchange Securities Trading Limited ("**SGX-ST**"). The registered office and principal place of business at 54 Pandan Road, Singapore 609292.

These condensed interim consolidated financial statements as at and for the three months and six months period ended 30 June 2026 comprise the Company and its subsidiaries (collectively, the "**Group**").

The primary activity of the Company is that of investment holding. The principal activities of the subsidiaries are as follows:

(a) Manufacturing and distribution of lab-grown diamonds;
(b) Collection and processing of food waste into animal feed, bio-fuel and other by-products, and the production and sale of agricultural machinery, fermentation and renewable resource equipment (the "**Food Waste Business**"); and
(c) Wholesale distribution of high-quality and affordable nutritional supplements (the "**Health Supplements Business**").

2. Basis of preparation

The condensed interim financial statements for the three months and six months period ended 30 June 2026 have been prepared in accordance with Singapore Financial Reporting Standards (International) ("**SFRS(I)**") 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last interim financial statements for the period ended 31 March 2026.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore Dollar which is the Company's functional currency.

2.1 New and amended standards adopted by the Group

A number of amendments to standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2 Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

Other than as disclosed in the condensed interim consolidated financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2025.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial period are included in the following note:

- Note 11 – Impairment for property, plant and equipment

Management reviews the Group's property, plant and equipment at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the recoverable amount of the property, plant and equipment is estimated to determine the amount of impairment.

During the current financial year, based on external and/or internal sources of information, there are impairment indicators for the Group's property, plant and equipment. The Group's management determined the recoverable amounts of the individual cash-generating units using value-in-use calculations, which involved significant judgements and estimates in estimating the gross and profit margins, expected growth rate and discount rate.

As at the reporting date, the net carrying amount of the Group's property, plant and equipment is disclosed in Note 11.

- Note 13 – Valuation of inventories

The Group measures the inventories in accordance with the accounting policy as disclosed in Note 2. The Group's management measured the inventories at the lower of cost and net realisable value. In ascertaining net realisable value, significant judgements and estimates are involved in estimating the expected selling prices less the estimated costs of completion and the estimated costs to be incurred in marketing, selling and distribution.

There was a provision made for inventory loss during the prior financial year which is on the basis of the purchase price of the inventory. The net carrying amount of the Group's inventories is disclosed in Note 13.

2.3 Going Concern

The Group incurred net cash used in operating activities of S$1,185,000 (HY2025: S$2,143,000) during HY2026. As at 30 June 2026, the Group had cash and cash equivalents of approximately S$11,000, while the Company had net current liabilities of approximately S$131,000 (31 December 2025: S$1,456,000) and net liabilities of approximately S$131,000 (31 December 2025: S$1,455,000).

Notwithstanding that the Group was in a net current asset position as at 30 June 2026, the Group's low cash balance, net cash used in operating activities, and the Company's net current liabilities and net liabilities position indicate the existence of a material uncertainty which may cast significant doubt on the Group's and the Company's ability to continue as going concerns.

Notwithstanding the above, the directors of the Company believe that the use of the going concern assumption in the preparation and presentation of the financial statements for the six-month period ended 30 June 2026 is appropriate after taking into consideration the following factors:

i. Management has prepared a cash flow projection for its operations for the next twelve months and is satisfied that the Group will have sufficient cash flow.

ii. The Group has plans to raise capital and obtain additional funds for working capital and the management will continue to evaluate various strategies to obtain alternative sources of finance where necessary to enable the Group to meet its obligations as and when they fall due. In this regard, the Company had, subsequent to the end of the financial period, (a) partially completed the placement of 100,000,000 new ordinary shares (the "**Placement Shares**") in the capital of the Company with Mr. Ma Ong Kee ("**Mr. Ma**") and Raffles Capital Limited ("**RCL**") on 30 July 2026 (the "**Placement**"), raising net proceeds of approximately S$2,856,000 pursuant to the allotment and issuance of an aggregate 72,000,000 Placement Shares to Mr. Ma and RCL, and (b) entered into an S$3.0 million interest-free loan with Mr. Cao Shixuan ("**Mr. Cao**") on 6 August 2026 (the "**August 2026 Loan**").

iii. The Group will take all necessary action to monetise its non-core assets, including but not limited to, the proposed disposal of Asian Eco Technology Pte. Ltd. ("**AET**"), of which approval from shareholders has been obtained at the extraordinary general meeting convened by the Company on 30 April 2026.

iv. The biomass carbon reduction system machines, intended for the pilot trial, have arrived at the factory and have successfully completed testing and commissioning. Concurrently, the Company is actively engaging with corporations across multiple countries and industries to expand into various regional and international markets.

    Concurrently, based on information provided by Colorful Paradise Agricultural Cooperation Co., Ltd. ("**CPAC**"), the Company's joint venture partner in Taiwan, the project has received grant support as an approved initiative by the Taiwan authorities, reflecting strong market demand for such machines. To date, orders have been placed for the biomass carbon reduction system machines, underscoring the product's viability. The Company views this as a positive development and will further strengthen its cooperation with CPAC to expand the deployment of the biomass carbon reduction system machines, including discussions on the appropriate business model and commercial arrangements going forward. In view of the grants received from the relevant authorities in Taiwan, the Company is currently in discussions with CPAC in relation to the joint fulfilment of such orders. The Company may also, with CPAC, expand the relevant businesses into the ASEAN region.

In relation to the non-binding memorandum of understanding with MLF Ingredients Sdn. Bhd. ("**MLF**"), the Company is in discussions with MLF on the proposed pricing of its potential high-protein animal nutrition products for the South Korea and United States markets. Concurrently, the Company is exploring collaborations with neighboring vendors to leverage their established sales networks to expand its global market reach, including in South Korea, the United States, Europe and Asia, while evaluating Malaysia as a potential manufacturing and production base for such products.

The Company possesses the technical know-how to derive high-quality food-grade protein ingredients from food valorization streams and plant-derived sources. The current formulation targets comprise approximately 40% protein derived from food industry by-products and valorization sources, including soy waste, brewer's extract residues and dairy waste streams, with the remaining 60% derived from plant-based ingredients. To validate the protein content of the product, the Company had commissioned an independent third-party laboratory test.

The Company is exploring commercialization opportunities for applications including premium animal feed, baby animal nutrition, senior meal replacement products and infant nutrition formulations, subject to applicable regulatory approvals and market requirements. Management believes the high-quality protein formulations may contribute to improved nutritional outcomes, enhanced digestibility, reduced mortality rates in young animal applications and overall improved health performance.

v. With respect to the Health Supplements Business, the Company is actively working to grow its health supplement sales by leveraging the health supplements license recently obtained by its supplier to expand marketing efforts and sales outreach across various regions of the People's Republic of China. In anticipation of increased demand, the Company is also working with its supplier to enhance production capacity through factory expansion and investments in additional machinery, while concurrently undertaking the necessary repackaging and production activities.

vi. The Group will continue to implement cost-cutting measures.

vii. In addition to the August 2026 Loan, as at the date of this announcement, approximately S$460,000 remains available for drawdown under the existing S$3.0 million interest-free loan with Mr. Cao pursuant to the interest-free loan agreement dated 7 October 2024 (the "**October 2024 Loan**"). For the avoidance of doubt, the October 2024 Loan is due to mature on 23 September 2026. As at the date of this announcement, the Company has made aggregate repayments of S$2.5 million in respect of the October 2024 Loan.

viii. Mr. Cao has indicated to the Company that he will continue to provide financial support and assistance, where necessary, to enable the Group to meet its obligations as and when they fall due.

In the event that the Group and the Company are unable to continue as going concerns, adjustments may have to be made to reflect the situation that assets may need to be realised other than in the normal course of business and at amounts which could differ significantly from the amounts at which they are recorded in the statements of financial position. In addition, the Group and the Company may have to provide for liabilities that might arise, and to reclassify non-current assets as current assets. No such adjustments have been made to these financial statements.

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segment and revenue information

The Group has three reportable segments as follows:
(a) The Health Supplements Business;
(b) Manufacturing and distribution of lab-grown diamonds; and
(c) Corporate segment which consists of an investment holding company which does not meet any of its quantitative thresholds for determining a reporting segment.

These operating segments are reported in a manner consistent with internal reporting provided to the former executive committee whose members were responsible for allocating resources and assessing the performance of each segment.

4.1 Reportable segments

	Lab-grown Diamond		Health Supplements Business		Corporate/other		Per consolidated financial statements	
	3 months period ended 30/06/2026 (Q2FY2026)	3 months period ended 30/06/2025 (Q2FY2025)	3 months period ended 30/06/2026 (Q2FY2026)	3 months period ended 30/06/2025 (Q2FY2025)	3 months period ended 30/06/2026 (Q2FY2026)	3 months period ended 30/06/2025 (Q2FY2025)	3 months period ended 30/06/2026 (Q2FY2026)	3 months period ended 30/06/2025 (Q2FY2025)
	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000
Revenue	-	-	1,288	1,521	-	-	1,288	1,521
Depreciation and amortisation	-	(7)	-	-	(2)	(24)	(2)	(31)
Finance cost	-	-	-	-	-	(2)	-	(2)
Segment (loss)/profit	(*)	(32)	243	263	(138)	(350)	105	(119)
Segment assets	396	184	4,698	1,297	1,308	1,053	6,402	2,534
Segment liabilities	(167)	(293)	(3,882)	(1,270)	(1,886)	(2,549)	(5,935)	(4,112)
Capital expenditure								
- Addition to property, plant and equipment	-	-	-	-	-	-	-	-

	Lab-grown Diamond		Health Supplements Business		Corporate / other		Per consolidated financial statements	
	6 months period ended 30/06/2026 (HY2026)	6 months period ended 30/06/2025 (HY2025)	6 months period ended 30/06/2026 (HY2026)	6 months period ended 30/06/2025 (HY2025)	6 months period ended 30/06/2026 (HY2026)	6 months period ended 30/06/2025 (HY2025)	6 months period ended 30/06/2026 (HY2026)	6 months period ended 30/06/2025 (HY2025)
	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000
Revenue	-	-	3,210	3,061	-	-	3,210	3,061
Depreciation and amortisation	-	(16)	-	-	(4)	(46)	(4)	(62)
Finance cost	-	-	-	-	-	(5)	-	(5)
Segment (loss)/profit	(*)	(64)	598	355	(250)	(690)	348	(399)
Segment assets	396	184	4,698	1,297	1,308	1,053	6,402	2,534
Segment liabilities	(167)	(293)	(3,882)	(1,270)	(1,886)	(2,549)	(5,935)	(4,112)
Capital expenditure								
- Addition to property, plant and equipment	-	-	-	-	-	-	-	-

4.2 Disaggregation of revenue

	Group		Group	
	3-months period ended 30/06/2026 (Q2FY2026)	3-months period ended 30/06/2025 (Q2FY2025)	6-months period ended 30/06/2026 (HY2026)	6-months period ended 30/06/2025 (HY2025)
	S$'000	S$'000	S$'000	S$'000
Principal geographical market				
People's Republic of China	1,288	1,521	3,210	3,061
Major product or service line and time of recognition				
Performance obligations satisfied at a point in time				
Sale of goods – Health supplements business	1,288	1,521	3,210	3,061

A breakdown of sales:

	Group		
	6-months ended 30/06/2026 (Unaudited)	6-months ended 30/06/2025 (Unaudited)	Inc/(Dec)
	S$'000	S$'000	%
Sales reported for the first six-month period	3,210	3,061	4.87
Operating profit/(loss) after tax before deducting non-controlling interests reported for first six-month period	348	(399)	n.m.

5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 30 June 2026 and 31 December 2025:

	Group		Company	
	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000	S$'000	S$'000
Financial assets measured at amortised cost				
Trade and other receivables #	6,327	2,257	*	10
Cash and cash equivalents	11	198	4	3
Amount due from subsidiaries	-	-	1,288	-
	6,338	2,455	1,292	13
Financial liabilities measured at amortised cost				
Trade and other payables *	(4,774)	(2,226)	(842)	(762)
Loan from an employee	(1,009)	(1,527)	(581)	(703)
Amount due to subsidiaries	-	-	(8)	(8)
	(5,783)	(3,753)	(1,431)	(1,473)

Excludes prepayments and GST receivables
* Excludes contract liabilities and GST payables

6. Other income

	Group			
	3-months period ended 30/06/2026 (Q2FY2026)	3-months period ended 30/06/2025 (Q2FY2025)	6-months period ended 30/06/2026 (HY2026)	6-months period ended 30/06/2025 (HY2025)
	S$'000	S$'000	S$'000	S$'000
Other income:				
Others				
- Government grant	2	2	2	4
- Building management income	207	-	357	-
- Miscellaneous	-	-	7	2
	209	2	366	6

7. Loss before income tax

7.1 Significant items

	Group			
	3-months period ended 30/06/2026 (Q2FY2026)	3-months period ended 30/06/2025 (Q2FY2025)	6-months period ended 30/06/2026 (HY2026)	6-months period ended 30/06/2025 (HY2025)
	S$'000	S$'000	S$'000	S$'000
Depreciation of property, plant and equipment				
- included in administrative expenses	2	31	4	62
Interest expenses on lease liabilities	-	2	-	5
Professional expenses				
- included in administrative expenses	49	86	60	142

8. Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

	Group			
	3-months period ended 30/06/2026 (Q2FY2026)	3-months period ended 30/06/2025 (Q2FY2025)	6-months period ended 30/06/2026 (HY2026)	6-months period ended 30/06/2025 (HY2025)
	S$'000	S$'000	S$'000	S$'000
Current income tax expenses	-	-	-	-
Current year	-	-	-	-
Reversal of prior year provision	-	-	-	-

As at 30 June 2026, the Group has unutilised tax losses of approximately S$18,246,000 (31 December 2025: S$18,246,000), which are available to offset future taxable profits of those corporate entities within the Group where these losses arise. The utilisation of these unutilised tax losses is subject to the agreement of the relevant tax authorities and compliance with the applicable provisions of the tax regulation in the jurisdictions which the corporate entities of the Group operate. The unutilised tax losses have no expiry dates.

Deferred tax assets arising from these unutilised tax losses and capital allowances of approximately S$3,102,000 (31 December 2025: S$3,102,000) have not been recognised in HY2026.

9. Dividends

No dividend for the period ended 30 June 2026 (30 June 2025: Nil) is recommended.

10. Net assets/(liability) value

	Group		Company	
	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)
Net assets/(liability) value(1) per ordinary share (cents)	0.55	(0.21)	(0.05)	(0.72)
No. of ordinary shares	263,510,200	201,010,200	263,510,200	201,010,200

Note:

(1) Net assets/(liability) value attributable to the owners of the Company

The calculation of net assets/(liability) value per ordinary share of the Group and the Company is based on 263,510,200 shares as at 30 June 2026 (31 December 2025: 201,010,200).

11. **Property, plant and equipment**

	Group			
	Leasehold buildings	**Plant and equipment**	**Furniture and fittings and office equipment**	**Total**
	S$'000	**S$'000**	**S$'000**	**S$'000**
Cost				
Balance at 1 January 2025	268	5,359	27	5,654
Additions	-	40	4	44
Disposal / Written off	(268)	(5,359)	-	(5,627)
Balance at 31 December 2025	-	40	31	71
Additions	-	-	-	-
Disposal / Written off	-	-	-	-
Balance at 30 June 2026	-	40	31	71
Accumulated depreciation and impairment				
Balance at 1 January 2025	60	5,092	20	5,172
Depreciation for the year	67	26	7	100
Disposal / Written off	(127)	(5,118)	-	(5,245)
Balance at 31 December 2025	-	-	27	27
Depreciation for the year	-	2	2	4
Balance at 30 June 2026	-	2	29	31
Carrying amount				
Balance at 31 December 2025	-	40	4	44
Balance at 30 June 2026	-	38	2	40

Note:
Right-of-use assets acquired under leasing arrangement are presented together with the owned assets of the same class.

12. Investment in subsidiaries

	Company	
	As at 30/06/2026 (Unaudited)	**As at 31/12/2025 (Audited)**
	S$'000	**S$'000**
Equity investments, at cost	4,020	4,020
Less: Impairment losses	(4,020)	(4,020)
Balance at 30 June 2026 / 31 December 2025	-	-
Impairment losses on equity investments		
Balance at the beginning and end of the period/year	(4,020)	(4,020)

(a) The details of the subsidiaries held by the Group and the Company are as follows:

Name of Company / Country of Incorporation	Principal activities	Percentage of effective equity interest held by the Group	
		30/06/2026	31/12/2025
		%	%
Held by the Company			
Metech Dynamics Pte Ltd. *Singapore*	General wholesale trade (including general importers and exporters) and wholesale trade of a variety of goods without a dominant product	100	100
Asian Green Tech Pte. Ltd. *Singapore*	Engineering design and consultancy services in energy management and clean energy system	100	100
Biovalor Innovations Pte. Ltd. (formerly known as Metech Diamond Pte. Ltd.) *Singapore*	Promoting and selling lab-grown diamonds and gemstones over the internet	100	100
Opulwell Biotechnology Pte. Ltd. (formerly known as Metech Diamond Solutions Pte. Ltd.) *Singapore*	Wholesale of health supplements	100	100
Held by Metech Dynamics Pte. Ltd.			
Zhongxin Minghua (Shanghai) International Trade Co., Ltd. *People's Republic of China*	General wholesale trade	100	100
Held by Asian Green Tech Pte. Ltd.			
Asian Eco Technology Pte. Ltd. *Singapore*	Manufacturing and distribution of lab-grown diamonds	80	80

13. Inventories

	Group	
	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000
Raw materials	-	-
Finished goods	-	-
	-	-

Movements in allowance

	Group	
	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000
Balance at 1 January 2026 / 2025	39	257
Write off impairment losses	-	(218)
Balance at 30 June 2026 / 31 December 2025	39	39

For the current financial period ended 30 June 2026, finished goods recognised in cost of sales amounted to S$ nil (31 December 2025: S$ nil) as the cost has been fully impaired in the 18-month financial period ended 31 December 2023 ("**FP2023**").

14. Trade receivables

	Group		Company	
	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000	S$'000	S$'000
Trade receivables	4,919	1,421	-	-

Trade receivables are non-interest bearing and generally has credit terms of 30 to 120 (31 December 2025: 30 to 120) days. Loss allowance for trade receivables is measured at an amount equal to lifetime expected credit losses.

The Group's credit risk exposure in relation to trade receivables are set out in the provision matrix as presented below. The Group's provision for loss allowance is based on past due as the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments.

	Lifetime expected loss rate	Gross carrying amounts	Lifetime expected credit losses	Net carrying amounts
	%	S$'000	S$'000	S$'000
Group				
As at 30/06/2026				
> 120 days	100	14	(14)	-
As at 31/12/2025				
Current	100	14	(14)	-

The movements in the allowance account used to record the impairment loss during the financial period / year are as follows:

	Group	
	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000
Balance at the beginning and end of the period/year	14	14

14. Other receivables

	Group		Company	
	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000	S$'000	S$'000
Other receivables – third parties	823	809	437	437
Advances	235	235	-	-
Deposit	1,019	464	*	10
Amount due from subsidiaries (non-trade)	-	-	9,101	7,864
	2,077	1,508	9,538	8,311
Less: Allowance for impairment losses	(672)	(672)	(8,250)	(8,301)
Financial assets	1,405	836	1,288	10
Prepayments	19	3	14	-
GST receivable	*	4	-	4
	1,424	843	1,302	14

Group level

i) *Other receivables – third parties*

As disclosed in the Company's announcement dated 13 December 2023, the Company has entered into a settlement agreement with Mr. Deng Yiming ("**Mr. Deng**") where Mr. Deng has agreed to, *inter alia*, pay the Company an amount of S$483,000 with interests accruing at a rate of 5.33% per annum, as awarded by the High Court of the Republic of Singapore. Mr. Deng is to pay in six (6) instalments, commencing from 15 January 2024. The Company has received RMB250,000 (approximately S$46,000) from Mr. Deng as at the date of this announcement. As at the date of this announcement, the Company remains in close contact with Mr. Deng and is following-up and monitoring closely on the receipt of the balance amount. The Company will subsequently make the appropriate announcement(s) as and when there are any material developments in this regard.

Below are the movements of impairment loss during HY2026 and FY2025:

	Group	
	As at 30/06/2026	As at 31/12/2025
	S$'000	S$'000
Balance at the beginning and end of the period/year	437	437

ii) *Advances*

Advance payments of S$235,000 in HY2026 and FY2025 consist of payment to vendors for inventories and to a former non-controlling interest for purchase of lab grown diamonds and business travelling expenses which had been fully impaired in FP2023.

The below are the movements of impairment loss during HY2026 and FY2025:

	Group	
	As at 30/06/2026	**As at 31/12/2025**
	S$'000	**S$'000**
Balance at the beginning and end of the period/year	235	235

iii) Deposits

Deposits included rental deposit, deposits placed with the professional parties and in relation to the office at 54 Pandan Road.

Company level

i) Amounts due from subsidiaries (non-trade)

Except for a non-trade balance of S$2,798,000 (FY2025: S$2,798,000) due from subsidiaries as at 30 June 2026, which is non-trade in nature, unsecured, interest bearing at 6% per annum, the remaining non-trade balance of S$6,303,000 (FY2025: S$5,066,000) due from subsidiaries are unsecured, interest-free and repayable on demand.

The movements in the allowance account used to record the impairment loss during the financial period / year are as follows:

	Company	
	As at 30/06/2026 (Unaudited)	**As at 31/12/2025 (Audited)**
	S$'000	**S$'000**
Balance at 1 January 2026 / 2025	7,864	8,238
Reversal of impairment loss recognised in profit or loss	(51)	(374)
Balance at 30 June 2026 / 31 December 2025	7,813	7,864

15. Cash and cash equivalents

	Group		Company	
	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000	S$'000	S$'000
Cash and bank balances	11	198	4	3

Bank balances are interest-bearing. Interest earned during the current and previous financial period are considered insignificant.

16. Discontinued operations and disposal group classified as held for sale

The Company had, on 4 October 2025, announced the proposed disposal of its entire shareholdings of 80% of the issued and paid-up share capital of AET to Wuhan Xilu Trading Co., Ltd. (the "**Proposed Disposal**").

The Company had, on 30 April 2026, obtained Shareholders' approval for the proposed disposal of its 80% stake in AET. Upon completion of the Proposed Disposal, AET will cease to be a subsidiary of the Company. The Company will make the relevant announcement(s) upon completion of the Proposed Disposal in accordance with the Catalist Rules.

17. Share capital

	As at 30/06/2026		As at 31/12/2025	
	No. of shares	Amount S$'000	No. of shares	Amount S$'000
Issued and fully paid:				
Balance at beginning of interim period/year	201,010,200	190,510	201,010,200	190,510
Issuance of ordinary shares	62,500,000	1,500	-	-
Balance at the end of the period/year	263,510,200	192,010	201,010,200	190,510

The allotment and issuance of 62,500,000 new ordinary shares in the capital of the Company (the "**Conversion Shares**") during the reporting period was pursuant to the loan conversion agreement dated 24 March 2026 entered into with Mr. Cao. Pursuant to the loan conversion agreement, the Company and Mr. Cao had agreed to allot and issue the 62,500,000 Conversion Shares as a partial repayment of the October 2024 Loan of an aggregate amount of S$1,500,000, at an issue price of S$0.024 per Conversion Share (the "**Debt Capitalisation**").

The 62,500,000 Conversion Shares were allotted and issued to Mr. Cao on 2 June 2026. Accordingly, the Debt Capitalisation was completed and announced by the Company on the same date. The Debt Capitalisation did not result in any new cash proceeds for the Company.

Save as disclosed above, there were no other changes in the Company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities or for any other purpose since the end of the previous period reported on, being 31 March 2026.

The total number of issued shares excluding treasury shares as at 30 June 2026 and 31 December 2025 were 263,510,200 shares and 201,010,200 shares, respectively.

The Company had no outstanding convertibles, treasury shares and subsidiary holdings as at 30 June 2026 and 30 June 2025, respectively.

There were no sales, transfers, cancellation and/or use of treasury shares or subsidiary holdings during the three-month and six-month periods ended and as at 30 June 2026.

18. Other reserves

Other reserves

	Group	
	As at 30/06/2026	As at 31/12/2025
	S$'000	S$'000
Balance at the beginning and end of the period/year	(319)	(319)

Translation reserve

	Group	
	As at 30/06/2026	As at 31/12/2025
	S$'000	S$'000
Balance at beginning of interim period/year	(6)	20
Exchange differences on currency translation differences	16	(26)
Balance at the end of the period/year	10	(6)
Other reserves at the end of the period/year	(309)	(325)

19. Non-controlling interest

The non-controlling interest relates to the remaining 20% shares in AET not held by the Company.

20. Trade and other payables

	Group		Company	
	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)	As at 30/06/2026 (Unaudited)	As at 31/12/2025 (Audited)
	S$'000	S$'000	S$'000	S$'000
Trade payables	3,877	1,402	-	-
Sundry creditors	558	460	526	433
GST payable	6	-	6	-
Accruals for:				
- professional fees	60	108	56	94
- staff costs	87	79	68	58
- directors' fee	192	177	192	177
Amount due to subsidiaries (non-trade)	-	-	8	8
Loan/Advances from an employee *	1,009	1,527	581	703
	5,789	3,753	1,437	1,473

The non-trade balances due to subsidiaries are unsecured, interest-free and repayable on demand.

* The loan/advances from an employee are unsecured, interest-free, and the amounts are repayable within one year or on demand.

The Group had, on 7 October 2024, entered into an interest-free loan agreement for the October 2024 Loan. Any drawdown under this loan is repayable 12 months from the date of the agreement, save for any events of default, pursuant to which the monies shall immediately fall due (the "**Maturity Date**"). The Maturity Date of the October 2024 Loan, which was neither utilised nor converted pursuant to the debt capitalisation agreement dated 24 March 2026 (the "**Debt Capitalisation Agreement**"), was subsequently extended for an additional six (6) months from the date of the Debt Capitalisation Agreement.

As at 30 June 2026, approximately S$2.5 million had been drawn down and utilised by the Company under the October 2024 Loan amounting to S$3.0 million.

Save as disclosed in this announcement, the Group does not have any other borrowings and/or debt securities as at 30 June 2026 and 31 December 2025.

21. Subsequent events

a. The Company had, on 26 June 2026, announced the Placement, and had, on 30 July 2026, partially completed the Placement of 72,000,000 Placement Shares to Mr. Ma and RCL, raising net proceeds of approximately S$2,856,000 (the "**Net Proceeds**").

b. The Company had, on 6 August 2026, entered into a S$3.0 million interest-free loan agreement with Mr. Cao for the August 2026 Loan.

OTHER INFORMATION REQUIRED PURSUANT TO APPENDIX 7C OF THE CATALIST RULES

1. **Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.**

The condensed interim consolidated statement of profit or loss and other comprehensive income of Metech International Limited (the "**Company**", and its subsidiaries, collectively, the "**Group**") as at 30 June 2026 and the related condensed interim consolidated statements of financial position, condensed interim consolidated statement of changes in equity, condensed profit or loss and other comprehensive income consolidated and statement of cash flows for the three-month and six-month periods then ended and certain explanatory notes have not been audited or reviewed.

2. **Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter).**

Not applicable.

2A. **Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:**

(a) **Updates on the efforts taken to resolve each outstanding audit issue.**

(b) **Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.**

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable.

3. **A review of the performance of the group, to the extent necessary for a reasonable understanding of the Group's business. It must include a discussion of the following:**

(a) **any significant factors that affected the turnover, costs, and earnings of the Group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**

Review for the performance of the Group for HY2026 and Q2FY2026

(i) **Revenue**

In Q2FY2026, the Group's revenue decreased by approximately S$0.23 million from approximately S$1.52 million in Q2FY2025 to approximately S$1.29 million in Q2FY2026, mainly due to slower production cycles from suppliers of the Health Supplements Business which affected the delivery of the orders.

In HY2026, the Group generated revenue of approximately S$3.21 million, representing a slight increase of approximately S$0.15 million, as compared to revenue of approximately S$3.06 million in HY2025.

(ii) **Cost of sales**

The Group's cost of sales decreased by approximately S$0.24 million, from approximately S$1.28 million in Q2FY2025 to approximately S$1.04 million in Q2FY2026. The decrease in cost of sales is generally in line with the decrease in sales generated in Q2FY2026.

In HY2026, the Group's cost of sales decreased by approximately S$0.11 million, from approximately S$2.72 million in HY2025 to approximately S$2.61 million in FY2026. The decrease in cost of sales was mainly due to the Company's negotiation for lower purchase prices with its suppliers for the Health Supplements Business, leading to a higher gross profit margin achieved.

(iii) **Gross profit**

As a result of the above, the Group generated a gross profit of approximately S$247,000 in Q2FY2026 as compared to a gross profit of approximately S$246,000 in Q2FY2025.

In HY2026, the Group recorded a gross profit of approximately S$0.61 million, as compared to a gross profit of approximately S$0.34 million in HY2025.

Accordingly, this represented an increase in gross profit margin of approximately 7.81%, from approximately 11.04% in HY2025 to approximately 18.85% in HY2026.

(iv) Other income

In Q2FY2026, the Group recorded an increase in other income of approximately S$0.21 million, from approximately S$2,000 in Q2FY2025 to approximately S$0.21 million in Q2FY2026. The increase was mainly due to the building management income generated from the management of the building at 54 Pandan Road.

In HY2026, the Group recorded an increase in other income of approximately S$0.36 million, from approximately S$6,000 in HY202 to approximately S$0.37 million in HY2026. The increase was mainly due to the building management income generated from the management of the building at 54 Pandan Road.

(v) Administrative expenses

In Q2FY2026, administrative expenses decreased by approximately S$4,000, from approximately S$355,000 in Q2FY2025 to approximately S$351,000 in Q2FY2026. This decrease was mainly attributed to the decrease in depreciation charged during the financial period.

In HY2026, administrative expenses decreased by approximately S$0.09 million from approximately S$0.71 million in HY2025 to approximately S$0.6 million in HY2026. This decrease was mainly attributed to the lower professional fees incurred and depreciation charged during the financial period.

(vi) Finance costs

Finance costs of approximately S$2,000 and S$5,000 were incurred in Q2FY2025 and HY2025, respectively as compared to nil in Q2FY2026 and HY2026.

Finance costs in Q2FY2025 and HY2025 were attributed to the amortisation of interest expense from lease liabilities. No finance costs were incurred in Q2FY2026 and HY2026 following the termination of the relevant lease in FY2025.

(vii) Profit/(Loss) from continuing operations

As a result of the above, the Group's profit before and after income tax increased by approximately S$0.22 million, reversing from a loss of approximately S$0.11 million in Q2FY2025, to a profit of approximately S$0.11 million in Q2FY2026, mainly due to higher gross profit margin recorded, building management income generated from the management of the building at 54 Pandan Road and lower expenses incurred as compared to Q2FY2025. No income tax expenses were incurred as the Group has unutilised tax losses that can be used to offset against the profit recorded in Q2FY2026.

The Group's profit before and after income tax increased by approximately S$0.72 million, reversing from a loss of approximately S$0.37 million in HY2025, to a profit of approximately S$0.35 million in HY2026, mainly due to higher gross profit margin recorded, building management income generated from the management of the building at 54 Pandan Road and lower expenses incurred as compared to HY2025. No income tax expenses were incurred as the Group has unutilised tax losses that can be used to offset against the profit recorded in HY2026.

Loss from discontinued operations amounted to less than S$1,000 in Q2FY2026, as compared to approximately S$10,000 in Q2FY2025. Similarly, loss from discontinued operations amounted to less than S$1,000 in HY2026, as compared to approximately S$27,000 in HY2025.

(viii) Foreign currency translation difference

Foreign currency translation difference was a gain of approximately S$2,000 in 2QFY2026, as compared to a loss of S$3,000 in 2QFY2025. This was mainly due to the fluctuation of foreign currency exchange rates between the US Dollar ("**USD**") and Singapore Dollar ("**SGD**"), and between SGD and Chinese Yuan ("**RMB**") during the financial period.

Foreign currency translation difference was a gain of approximately S$16,000 in HY2026, as compared to a loss of S$2,000 in HY2025. This was mainly due to the fluctuation of foreign currency exchange rates between the US Dollar ("**USD**") and Singapore Dollar ("**SGD**"), and between SGD and Chinese Yuan ("**RMB**") during the financial period.

(b) any material factors that affected the cash flow, working capital, assets or liabilities of the Group during the current financial period reported on

Condensed interim statements of financial position

Assets

(i) Property, plant and equipment decreased by approximately S$4,000, from approximately S$0.44 million as at 31 December 2025 to approximately S$0.40 million as at 30 June 2026. The decrease was due to the depreciation charges recorded in HY2026.

(ii) Trade and other receivables had increased by approximately S$4.08 million, from approximately S$2.26 million as at 31 December 2025 to approximately S$6.34 million as at 30 June 2026. The increase was mainly attributed to recognition of trade receivables arising from the sale of health supplements, and deposits placed in relation to the office premises at 54 Pandan Road.

(iii) Cash and bank balances have decreased by approximately S$187,000 from approximately S$198,000 as at 31 December 2025 to approximately S$11,000 as at 30 June 2026 and the movements as reflected in the statement of cash flows are explained below.

(iv) Disposal group assets classified as held for sale of approximately S$8,000 as at 30 June 2026 are mainly related to the assets of AET. Please refer to Note 16 for further information of the Proposed Disposal.

Liabilities

(v) Trade and other payables had increased by approximately S$2.04 million from approximately S$3.75 million as at 31 December 2025 to approximately S$5.79 million as at 30 June 2026. The increase was due to the recognition of trade creditors arising from the Health Supplements Business and the additional drawdown of the Second Loan, which was partially offset by the decrease in other payables.

(vi) Liabilities directly associated with disposal group classified as held for sale of approximately S$0.15 million are mainly related to the liabilities of AET. Please refer to Note 16 for further details of the Proposed Disposal.

Working capital

The Group had recorded an improvement in its working capital position by approximately S$1.87 million, reversing from a negative working capital position of S$1.44 million as at 31 December 2025 to a positive working capital position of S$0.43 million as at 30 June 2026. The improvement was mainly attributable to (a) an increase in trade and other receivables of approximately S$4.08 million, and (b) the debt capitalisation exercise for an aggregate amount of S$1.50 million which was completed on 2 June 2026, which was partially offset by an increase in trade and other payables of approximately S$2.04 million.

Condensed interim consolidated statement of cash flows

Q2FY2026

The Group recorded a slight increase in net cash used in operating activities of approximately S$0.08 million, from approximately S$0.69 million in Q2FY2025, to approximately S$0.77 million in Q2FY2026. This was mainly due to (a) a profit before income tax generated by the Group in Q2FY2026 as compared to a loss before income tax in Q2FY2025 and (b) an increase in trade and other payables, which was partially offset by an increase in trade and other receivables.

No cash was generated from or utilised in investing activities in Q2FY2026, as compared to S$4,000 in Q2FY2025, which was used in the acquisition of plant and equipment.

Net cash generated from financing activities decreased by approximately S$0.14 million, from approximately S$0.91 million in Q2FY2025 to approximately S$0.77 million in Q2FY2026. The decrease was mainly due to lower drawdown of the loan from an employee, partially offset by the absence of cash outflows in Q2FY2026 in relation to the lease liabilities which were terminated in FY2025.

As a result of the above, the Group's cash and cash equivalents as at 30 June 2026 increased by approximately S$3,000, from approximately S$8,000 as at 1 April 2026, to approximately S$11,000 as at the end of Q2FY2026, after taking into consideration the gain due to currency translation on cash and cash equivalents of approximately S$2,000.

<u>HY2026</u>

The Group recorded decrease in net cash used in operating activities of approximately S$0.95 million, from approximately S$2.14 million in HY2025 to approximately S$1.19 million in HY2026. This was mainly due to (a) a profit before income tax generated by the Group in HY2026 as compared to a loss before income tax in HY2025 and (b) an increase in trade and other payables, which was partially offset by an increase in trade and other receivables.

No cash was generated from or utilised in investing activities in HY2026, as compared to S$0.12 million in HY2025. The cash generated during HY2025 was mainly from the proceeds from the disposal of plant and equipment, which was partially offset by the acquisition of plant and equipment.

Net cash generated from financing activities of the Group increased by approximately S$0.10 million, from approximately S$0.88 million in HY2025 to approximately S$0.98 million in HY2026. The increase was due to the drawdown of the loan from an employee, partially offset by the absence of cash outflows in HY2026 in relation to the lease liabilities which were terminated in FY2025.

As a result of the above, the Group's cash and cash equivalents as at 30 June 2026 decreased by approximately S$203,000 from approximately S$198,000 as at 1 January 2026 to approximately of S$11,000 as at 30 June 2026, after taking into consideration the gain due to currency translation on cash and cash equivalents of approximately S$16,000.

4. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable as no specific forecast or a prospect statement was previously issued.

5. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next operating period and the next 12 months

<u>The Health Supplements Business</u>

The Company is actively working to grow its health supplements sales by leveraging the health supplements license recently obtained by its supplier to expand marketing efforts and sales outreach across various regions of the People's Republic of China. In anticipation of increased demand, the Company is also working with its supplier to enhance production capacity through factory expansion and investments in additional machinery, while concurrently undertaking the necessary repackaging and production activities.

The health products market is increasingly shifting towards personalised wellness, as consumers seek effective, science-backed solutions tailored to their individual needs. The Company notes these emerging trends, including but not limited to, the following:

(a) Personalised Wellness: Consumers are seeking tailored experiences for their respective individual needs;

(b) Gut Health: Growing interest in gut-related products, such as probiotics, prebiotics, and gut-friendly foods.

(c) Mental Wellness: Stress management, mindfulness, and mental health products.

(d) Functional Foods and Beverages: Products with added health benefits like energy boosters, digestive aids, and brain food are in demand.

(e) Digital Health: Virtual health services and digital wellness solutions such as health tracking applications and wearables.

The Food Waste Business

The biomass carbon reduction system machines, intended for the pilot trial, have arrived at the factory and have successfully completed testing and commissioning. Concurrently, the Company is actively engaging with corporations across multiple countries and industries to expand into various regional and international markets.

Concurrently, based on information provided by CPAC, the Company's joint venture partner in Taiwan, the project has received grant support as an approved initiative by the Taiwan authorities, reflecting strong market demand for such machines. To date, orders have been placed for the biomass carbon reduction system machines, underscoring the product's viability. The Company views this as a positive development and will further strengthen its cooperation with CPAC to expand the deployment of the biomass carbon reduction system machines, including discussions on the appropriate business model and commercial arrangements going forward. In view of the grants received from the relevant authorities in Taiwan, the Company is currently in discussions with Colorful Paradise Agricultural Cooperation Co., Ltd. in relation to the joint fulfilment of such orders. The Company may also, with Colorful Paradise Agricultural Cooperation Co., Ltd., expand the relevant businesses into the ASEAN region.

In addition, in relation to the memorandum of understanding ("**MOU**") with MLF, and as disclosed in the Company's monthly update announcement for the month of July on 31 July 2026, the Company is in discussions with MLF on the proposed pricing of its potential high-protein animal nutrition products for the South Korea and United States markets. Concurrently, the Company is exploring collaborations with neighboring vendors to leverage their established sales networks to expand its global market reach, including in South Korea, the United States, Europe and Asia, while evaluating Malaysia as a potential manufacturing and production base for such products.

The Company is exploring commercialization opportunities for applications including premium animal feed, baby animal nutrition, senior meal replacement products and infant nutrition formulations, subject to applicable regulatory approvals and market requirements. Management believes the high-quality protein formulations may contribute to improved nutritional outcomes, enhanced digestibility, reduced mortality rates in young animal applications and overall improved health performance.

Subject to the entry into definitive agreements between MLF and CPAC, the Company is of the view that the proposed collaborations with MLF and CPAC will increase the revenue stream and improve prospects of the Group, so as to enhance shareholders' value.

The Lab-grown Diamond Business

The Company conducts the Diamond Business through AET, the Company had on 30 April 2026 obtained shareholders' approval for the Disposal, and is in the midst of working with the counterparty in completing the Proposed Disposal.

6. If a decision regarding dividend has been made:

(a) Whether an interim (final) ordinary dividend has been declared (recommended); and
No.

(b) (i) Amount per share
Not applicable.

(ii) Previous corresponding period
No dividend has been declared or recommended for the previous corresponding period.

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).
Not applicable.

(d) The date the dividend is payable
Not applicable.

(e) The date on which Registrable Transfers received by the Company (up to 5.00 pm) will be registered before entitlements to the dividend are determined.
Not applicable.

7. If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

No dividend has been declared or is recommended as the Group is currently focused on its business expansion and restructuring, and the Group currently does not have accumulated profits available for the declaration of dividend.

8. Interested person transactions ("IPTs")

There was no interested person transaction amounting to S$100,000 and above during the financial period under review. The Group has not obtained a general mandate from its shareholders for IPTs.

9. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Rules

The Company hereby confirms that it has procured signed undertakings from all its directors and executive officers in the format set out in Appendix 7H of the Catalist Rules in accordance with Rule 720(1) of the Catalist Rules.

10. Negative Confirmation Pursuant to Rule 705(5) of the Catalist Rules

On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm to the best of our knowledge that nothing has come to the attention of the Board of Directors of the Company which may render the condensed interim financial statements for the three-month and six-month periods ended 30 June 2026 to be false or misleading in any material aspect.

11. Use of proceeds

The Company had, on 30 July 2026, announced the partial completion of the Placement of 72,000,000 Placement Shares. The Net Proceeds raised was S$2,856,000. The Company had, in the Placement announcement dated 26 June 2026, disclosed that all of the Net Proceeds would be utilised for general working capital purposes.

Subsequently, on 15 July 2026, the Company had reallocated the Net Proceeds to include the repayment of loans amounting to an aggregate amount of S$1,000,000 (the "**Reallocation**").

Pursuant to Rule 1204(22) of the Catalist Rules, as at 14 August 2026, the Company utilised the Net Proceeds as follows:

	Allocation (S$'000)	Allocation after the Reallocation (S$'000)	Amount utilised (S$'000)	Balance (S$'000)
General working capital purposes	**2,856**	**1,856**	**(334)**	**1,522**
Repayment of loans	**-**	**1,000**	**(1,000)**	**-**
Total		**2,856**	**(1,334)**	**1,522**

General working capital purposes refer to (a) professional fees of S$150,553, (b) employee benefits expenses of S$66,634, (c) Directors' fees of S$35,722 and (d) administrative and miscellaneous expenses of S$81,399.

12. Disclosure of acquisitions (including incorporations) and realisations of shares since the end of the previous reporting period pursuant to Rule 706A of the Catalist Rules

There were no such acquisitions or realisations which took place during HY2026.

On behalf of the Board of Directors

Pang Wei Hao
Chief Executive Officer and Executive Director

Er Kwong Wah
Independent Non-Executive Chairman

14 August 2026